AAV Vectors for Neurodegenerative Disease Gene Therapy

Introduction

Adeno-associated virus (AAV) vectors are the leading delivery platform for gene therapy targeting neurodegenerative diseases. These non-pathogenic viruses have become the vector of choice for CNS gene delivery due to their favorable safety profile, long-term expression, and ability to transduce both dividing and non-dividing cells["@aav2021"][@adenoassociated2022].

Biology of AAV Vectors

Structure

• Small, non-enveloped viruses (~25 nm diameter)
• Single-stranded DNA genome (~4.7 kb)
• Composed of icosahedral capsid protein shell
• Requires helper virus for replication

Serotypes

Over 100 naturally occurring AAV serotypes have been identified, each with distinct tissue tropisms:

• AAV1, AAV2, AAV5, AAV9: Neuronal transduction
• AAV9: Most commonly used for CNS delivery; crosses BBB in some contexts
• AAV-PHP.B/PHP.eB: Engineered variants with enhanced CNS transduction
• AAV2: Traditional choice; binds to heparan sulfate receptors

Packaging Capacity

• Maximum cargo: ~4.7 kb single-stranded DNA
• Limited for large gene delivery (e.g., full GBA1, large regulatory regions)
• Solutions: Split-intein systems, dual-vector approaches, minimal promoters

Mechanism of Action

...

Introduction

Adeno-associated virus (AAV) vectors are the leading delivery platform for gene therapy targeting neurodegenerative diseases. These non-pathogenic viruses have become the vector of choice for CNS gene delivery due to their favorable safety profile, long-term expression, and ability to transduce both dividing and non-dividing cells["@aav2021"][@adenoassociated2022].

Biology of AAV Vectors

Structure

• Small, non-enveloped viruses (~25 nm diameter)
• Single-stranded DNA genome (~4.7 kb)
• Composed of icosahedral capsid protein shell
• Requires helper virus for replication

Serotypes

Over 100 naturally occurring AAV serotypes have been identified, each with distinct tissue tropisms:

• AAV1, AAV2, AAV5, AAV9: Neuronal transduction
• AAV9: Most commonly used for CNS delivery; crosses BBB in some contexts
• AAV-PHP.B/PHP.eB: Engineered variants with enhanced CNS transduction
• AAV2: Traditional choice; binds to heparan sulfate receptors

Packaging Capacity

• Maximum cargo: ~4.7 kb single-stranded DNA
• Limited for large gene delivery (e.g., full GBA1, large regulatory regions)
• Solutions: Split-intein systems, dual-vector approaches, minimal promoters

Mechanism of Action

Delivery Process

Cell surface binding: AAV capsid binds to specific receptors (e.g., AAV9 binds to galactose)

Internalization: Receptor-mediated endocytosis

Endosomal escape: Capsid undergoes conformational changes

Nuclear entry: Virions traffic to nuclear pore

Vector genome release: Second-strand synthesis completes genome

Long-term expression: Vector genome persists as episome

Expression Characteristics

• Onset: 2-4 weeks for peak expression
• Duration: Can persist for years in non-dividing cells
• Cell type specificity: Can be engineered with cell-specific promoters
• Immune privilege: CNS has reduced immune surveillance

Advantages for Neurodegenerative Diseases

Non-pathogenic: No disease-causing capacity; minimal risk of insertional mutagenesis

Long-term expression: Single treatment can provide years of therapeutic benefit

Neuronal tropism: Naturally targets neurons and glia

Safety profile: Well-tolerated in clinical trials

BBB penetration: Some serotypes (AAV9) can cross with certain delivery methods

Manufacturing: Scalable production systems available

Challenges

Pre-existing immunity: ~60% of population has neutralizing antibodies to common serotypes

Cargo size limits: Cannot deliver large genes or regulatory elements

Dose-dependent toxicity: High doses associated with liver toxicity

Anterior-posterior gradient: Difficult to achieve uniform brain coverage

D dorsal root ganglion toxicity: Observed with some high-dose CNS deliveries

Manufacturing complexity: Expensive and challenging to produce at scale

Immunogenicity: T cell responses can eliminate transduced cells

Engineered Variants for CNS Delivery

Naturally Enhanced Serotypes

• AAV-PHP.B: Engineered variant with ~40x better mouse CNS transduction
• AAV-PHP.eB: Further improved CNS transduction
• AAV9: Best characterized for CNS; some BBB crossing ability

Engineering Strategies

• Capsid mutagenesis: Random or directed evolution
• Library screening: In vivo selection for CNS targeting
• Brain shuttle antibodies: Fusing antibodies to AAV capsids
• Masking: Reducing immune recognition while preserving function

Current Development Stage

Approved Therapies

No AAV gene therapies are currently approved specifically for neurodegenerative diseases. However, CNS-targeting AAV programs are in various stages:

Clinical Trials

• [Parkinson's disease](/diseases/parkinsons-disease): AAV-GAD, AAV-AADC, AAV-GDNF programs
• [Alzheimer's disease](/diseases/alzheimers-disease): AAV-NGF, AAV-APOE programs
• [Huntington's disease](/diseases/huntingtons): AAV-HTT-RNAi programs
• [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis): AAV-SOD1 programs

Pipeline by Indication

| Disease | Programs | Stage |
|---------|----------|-------|
| Parkinson's | 12+ | Phase I/II |
| Alzheimer's | 8+ | Preclinical/Phase I |
| Huntington's | 6+ | Preclinical |
| ALS | 5+ | Phase I/II |

Companies Developing AAV for Neurodegeneration

Major Players

• Spark Therapeutics (Roche): Pioneer in AAV gene therapy
• Voyager Therapeutics: CNS-focused AAV pipeline
• NeuExcell Therapeutics: AAV-based programs for CNS disorders
• Passage Bio: AAV delivery for CNS monogenic disorders

Pharmaceutical Partners

• Biogen: Multiple CNS AAV programs
• Novartis: Acquired AveXis for AAV capabilities
• Pfizer: CNS gene therapy division
• Sanofi: Partnering on rare disease gene therapy

Manufacturing

• Catalent: Leading AAV CDMO
• Thermo Fisher: Manufacturing services
• Baxter: Gene therapy manufacturing

Dosing and Delivery Methods

Intraparenchymal Injection

• Direct injection into target brain regions
• Stereotactic guidance for precision
• Limited distribution from injection site

Intrathecal Injection

• Injection into cerebrospinal fluid
• Better CNS distribution than intraparenchymal
• Targets spinal cord and lower brain

Intravenous Injection

• Least invasive route
• Requires AAV variants that cross BBB
• Highest systemic exposure

Convection-Enhanced Delivery

• Positive pressure infusion
• Improved bulk flow distribution
• Being explored for uniform brain coverage

Future Directions

Next-Generation Capsids

• Continued engineering for enhanced CNS tropism
• Reduced immunogenicity variants
• Redosable systems

Manufacturing Innovation

• Suspension cell culture systems
• Higher yields
• Reduced costs

Novel Applications

• CRISPR delivery for gene editing
• Base editing delivery
• RNA targeting with AAV-delivered Cas13

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Gene Therapy](/technologies/gene-therapy)
• [CRISPR Gene Editing](/technologies/crispr-gene-editing-neurodegeneration)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier-dysfunction)
• [AAV-GAD Gene Therapy](/therapeutics/avadel-gad-gene-therapy)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [LRRK2](/genes/lrrk2)
• [GBA](/genes/gba)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, AAV vector delivery to the brain (Molecular Therapy, 2021) (2021)](https://doi.org/10.1016/j.ymthe.2021.02.025)

[Unknown, Adeno-associated virus serotypes for gene therapy of the central nervousystem (Human Gene Therapy, 2022) (2022)](https://doi.org/10.1089/hum.2022.123)

[Unknown, Engineered AAV vectors for CNS gene therapy (Nature Reviews Drug Discovery, 2023) (2023)](https://doi.org/10.1038/s41573-023-00704-5)